SavedAdd your journal

Journals / Turkish Journal of Pediatrics / 2019 / Cilt: 61 - Sayı: 4

Two years of newborn screening for cystic fibrosis in Turkey: Çukurova experience

Ayşe Şenay ŞAŞİHÜSEYİNOĞLU
Derya Ufuk ALTINTAŞ
Atıl BİŞGİN
Dilek DOĞRUEL
Mustafa YILMAZ
Mahir SERBES
Pages
505–512
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But it is too early to determine the specificityand sensitivity of the program.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The severity of cystic fibrosis (CF) depends on the type of cystic fibrosistransmembrane conductance regulator (CFTR) mutation.
📊
Key Findings & Data:The primary goal ofnewborn screening (NBS) is to decrease morbidity, mortality and associateddisabilities.
💡
Conclusion & Impact:But it is too early to determine the specificityand sensitivity of the program.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

The severity of cystic fibrosis (CF) depends on the type of cystic fibrosistransmembrane conductance regulator (CFTR) mutation. The primary goal ofnewborn screening (NBS) is to decrease morbidity, mortality and associateddisabilities. The National NBS for CF programme was initiated in Turkey since01.01.2015. The aim of this study was to present two years of experience ofour CF center which is located in the south of Turkey. The study populationcomprised of infants who were born in Adana between 1 January 2015 - 31December 2016, referred to our CF center as part of NBS for CF and performedCFTR gene analysis. The infants were divided into three groups according tolaboratory tests and symptoms as CF, CRMS (cystic fibrosis transmembraneconductance regulator-related metabolic syndrome) and false positive NBS.Between January 1, 2015 and December 31, 2016, NBS was performed in77,437 newborns in Adana. Two hundred seven (0.26%) newborns screenedwere positive for CF. A total of 184 infants were included to the study. Wereported 12 babies as CF with an incidence of 1:6,452. The babies diagnosed asCF constituted 6.5% of positive CF NBS. Rest of study group diagnosed withCRMS/CFSPID (54/184, 29.5%) and false positive (118/184, 64%). Positivepredictive value (PPV) of NBS was 6.5%. The most common CFTR mutationswere 508del, p.F1052L and p.L997 F. The implementation of CF-NBS programhas been successful in Turkey. But it is too early to determine the specificityand sensitivity of the program.

🔖

Cite This Article

ŞAŞİHÜSEYİNOĞLU, A. Ş., ALTINTAŞ, D. U., BİŞGİN, A., DOĞRUEL, D., YILMAZ, M., SERBES, M. (2019). Two years of newborn screening for cystic fibrosis in Turkey: Çukurova experience. Turkish Journal of Pediatrics, Cilt: 61 - Sayı: 4, 505–512. https://ajindex.com/articles/411898

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Radivojevic D, Sovtic A, Minic P, et al. Newborn screening for cystic fibrosis in Serbia: A pilot study. Pediatr Int 2013; 55: 181-184
  2. Gürson CT, Sertel H, Gürkan M, Pala S. Newborn screening for cystic fibrosis with the chloride electrode and neutron activation analysis. Helv Paediatr Acta 1973; 28: 165-174
  3. Lilley M, Christian S, Hume S, et al. Newborn screening for cystic fibrosis in Alberta: Two years of experience. Paediatr Child Health 2010; 15: 590-594
  4. Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. J Cyst Fibros 2015; 14: 419-430
  5. Schaefer JF, Hector A, Schmidt K, et al. A semiquantitative MRI-Score can predict loss of lung function in patients with cystic fibrosis: Preliminary results. Eur Radiol 2018; 28: 74-84
  6. Sosnay PR, White TB, Farrell PM, et al. Diagnosis of cystic fibrosis in nonscreened populations. J Pediatr 2017; 181: S52-S57. e2
  7. Farriaux JP, Vidailhet M, Briard ML, Belot V, Dhondt JL. Neonatal screening for cystic fibrosis: France rises to the challenge J. Inherit Metab Dis 2003; 26: 729- 744
  8. Levy H, Nugent M, Schneck K, et al. Refining the continuum of CFTR-associated disorders in the era of newborn screening. Clin Genet 2016; 89: 539-549
  9. Ren CL, Borowitz DS, Gonska T, et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis. J Pediatr 2017; 181: S45-S51.e1
  10. Doğum istatistikleri. Available at: www.tuik.gov.tr (Accesed on 05.11.2017)
  11. World Medical Association (WMA). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-3045
  12. Cinel G, Doğru D, Yalçın E, Özçelik U, Gürcan N, Kiper N. Sweat conductivity test: Can it replace chloride titration for cystic fibrosis diagnosis? Turk J Pediatr 2012; 54: 576-582
  13. Ersu R, Çakır E. Kistik Fibrozis Yenidoğan Tarama Testi ile Tanı Alan Hastaları İzleme Rehberi.T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu, 2015. Available at:http://www.kistikfibrozisturkiye. org/files/admin/KF_yenidogan_tarama_rehberi.pdf (Accesed on 22.04.2016)
  14. Farrell PM, Rosenstein BJ, White TB, et al; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4-S14
  15. Farrell PM, White TB, Howenstine MS, et al. Diagnosis o